Search Results

<< Go back to the Podcast page EPISODE 23: WHAT TO KNOW ABOUT HINDGUT & APPENDICEAL NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE What are Hindgut NETs (distal colon and rectum) and how are they treated? How is rectal NET different from rectal cancer? What makes appendiceal NETs difficult to diagnose? Dr. Hagen Kennecke from Providence Cancer Institute in Portland, Oregon shares insights on the diagnosis and management of Hindgut NETs and appendix NET. MEET DR. HAGEN KENNECKE Dr. Hagen Kennecke is a Medical Oncologist and Medical Director of GI Oncology at Providence Cancer Institute and Associate Member of the Chiles Research Institute in Portland, Oregon. He has worked passionately to improve the treatment, education and outcomes of those affected by neuroendocrine tumors. Dr. Kennecke is an active clinician researcher, the recipient of numerous research awards and has authored numerous guidelines on the treatment of neuroendocrine tumors. He is a member of the US NCI GI Steering Committee and is a prior member of the NCI-NET Task Force, and has worked extensively within the neuroendocrine community including NANETS, Carcinoid Cancer Foundation, LACNETS and Healing NETS. TOP 10 QUESTIONS What are hindgut NETs? Where are they located? What are the different types of hindgut NETs? How are hindgut NETs found? What are the symptoms of a hindgut NET? What types of labs, scans, or testing is done to determine if someone has a hindgut NET? Could you discuss why people with appendix NET often have a challenging time getting a diagnosis. How is rectal NET different from rectal cancer? What are some ways that hindgut NETs differ from other types of NETs? What makes rectal NET unique? How do you decide if the hindgut NET(s) can be surgically removed? What type of surgeon would make that determination? There are people diagnosed with appendix NET who have been told by their doctor to have a hemicolectomy. What is your opinion about this? How are hindgut NETs treated medically or nonsurgically? How are treatments sequenced? How are the treatments different from other NETs? How are hindgut NETs monitored What types of bloodwork or tests should be done and how often should they be done? What is the best type of scan for hindgut NETs? What are clinical trials we should be aware of or exciting new treatments in the pipeline for hindgut NETs? And what words of hope would you like to share with the NET community? RESOURCES WATCH https://www.youtube.com/watch?v=2mfxKxBYdoY Bob Shares His NET Journey READ An Update on Appendiceal Neuroendocrine Tumor s Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines - December 2022 Are Hemicolectomies Justified for Appendiceal Neuroendocrine Tumours Smaller Than 2 CM? Hemicolectomy Versus Appendectomy for Patients with Appendiceal Neuroendocrine Tumours 1-2 CM in Size: A Retrospective, Europe-Wide, Pooled Cohort Study NANETS Guidelines Library DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 34: NET TREATMENTS: FOCUS ON PRRT Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. MEET DR. RIHAM EL KHOULI, MD, PHD Associate Professor of Radiology, UK College of Medicine Chief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics (NM/MI&R) Director, Radiotheranostics Program University of Kentucky Dr. Riham El Khouli, MD PhD, is the director of the Radiotheranostics program and Chief of the division of NM/MI&R at the University of Kentucky and an Associate Professor of Radiology, Nuclear Medicine and Molecular Imaging at UK school of Medicine. The Radiotheranostics Program at UK is a multidisciplinary program that provides state of art standard of care clinical radiopharmaceutical therapy (RPT) techniques as well as a robust research program that constantly runs multiple RPT clinical trials aiming to explore new RPT management options for various cancers. Dr. El Khouli is fellowship trained double board certified, ABR and ABNM, academic Nuclear Radiologist with two decades of clinical and research experience. Her research initially focused on the evaluation and improvement of the acquisition and interpretation of advanced MRI techniques such as dynamic contrast enhanced (DCE) MRI, Diffusion weighted imaging (DWI), and 1H MR Spectroscopy in breast cancer. On 2013, Dr. El Khouli started a new journey in Nuclear Medicine, Molecular Imaging and Radioheranostics (NM/MI&R) and completed a nuclear medicine and dedicated PET/CT fellowships. During her new training, her passion toward molecular imaging and PET/CT grew and she participated in multiple nuclear medicine and PET/CT related research projects. Dr. El Khouli is passionate about research and education and active in the field of neuroendocrine tumor. She is one of the key team members of the dedicated biweekly intramural NET tumor boards. She also attended and presented in multiple regional NANETS and NET awareness group meetings (NCAN). Dr. El Khouli serves as a peer reviewer for multiple prestigious Journals such as Radiology and Radiographics, among others, and is an active member of the Radiologic Society of North America (RSNA), Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the American College of Radiology (ACR). She serves as an active member of the RSNA Awards Committee, RSNA Scientific Abstract Review Committee, and Radiographic NMMI review panel committee. Dr. El Khouli is an active panel member of multiple ACR Appropriateness Criteria Panels. TOP TEN QUESTIONS ABOUT NET TREATMENTS: What is PRRT? How does it work? What is theranostics and what does it mean? What are the terms radiotheranostics, radiopharmaceutical, radioligand therapy, PRRT? How do you determine who is eligible for PRRT? When is PRRT given in one’s treatment journey? How does PRRT differ from other treatments? What are the common side effects of Lutathera? Does Lutathera have long-lasting effects? Would receiving Lutathera affect one’s blood counts? How might Lutathera affect one’s liver function? When, if ever is there concern about liver failure? How might PRRT affect my quality of life and my day-to-day ability to work and function? What is the risk and effects of radiation with receiving Lutathera? What precautions do I need to follow? Can I hug my child? Can I pet my dog? Would receiving Lutathera cause someone to be immunocompromised? How to you decide who should get PRRT? What is peritoneal disease and how effective is PRRT with peritoneal disease? How do you assess the response to PRRT? What advances in PRRT are you most excited about? RESOURCES PRRT Clinical Trials PRRT Resources WATCH https://www.youtube.com/watch?v=oSqUgq6QdnM May 2024 LACNETS Educational Event with Dr. Aman Chauhan: "High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer" DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Newly Diagnosed < Back to Topics Play Video Play Video 01:37:36 "The Latest in the Management of Functional Neuroendocrine Cancers • Jan, 2026 • Dr. Del Rivero Join this @NCFCancer educational patient event for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), and other hormone-related issues. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. Potential Topics: Functional NET, Hormone-producing, Insulinoma, Gastrinoma, VIPoma, Zollinger-Ellison syndrome (ZES), Carcinoid, Hypoglycemia, Diarrhea, Flushing ABOUT DR. JAYDIRA DEL RIVERO Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. For more information, visit https://www.ncf.net/events/jan2026 Play Video Play Video 17:45 04. NETs 101: NET Terms & Concepts You Need to Know • Bassam Sonbol, MD • Arizona • @NCFCancer ⁩ Play Video Play Video 25:45 "NETS 101" • Jaydira Del Rivero, MD • 2023 NET Cancer Day Symposium @NCFCancer Jaydira Del Rivero, MD • 2023 NET Cancer Day Symposium • Santa Monica, CA Speaker: Jaydira Del Rivero, MD Medical Oncologist Endocrinologist National Cancer Institute, NIH For more information, visit LACNETS.org. Play Video Play Video 35:16 "Understanding NET Diagnosis" with Dr. Chandrasekharan • 2024 #LACNETS Patient Conference 2. "Understanding NET Diagnosis" with #Dr.Chandrasekharan Our 2024 LACNETS Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET) patients and caregivers to deepen your understanding of NETs. Whether you are newly diagnosed or have been living with NET for many years, we encourage you to attend: - Learn from top NET experts from across North America on a range of topics relevant to the NET patient journey. - Topics include work-ups, scans, surgery, carcinoid crisis, liver-directed therapy, PRRT, systemic treatments, treatment sequencing, NET guidelines, and clinical trials. - Gain insight into NET decision-making through the NET tumor board panel discussion. - Hear stories from NET patients and caregivers. - Join virtually, where you can pause, rewind, or replay. - There is no cost to attend. This event is made possible by the generosity of donors and sponsors. #LACNETS #neuroendocrinecancer #clinicaltrials #lungcancer #NETcancer #Letstalkaboutnets For more information, visit LACNETS.org. Play Video Play Video 21:51 NETS 101: Overview of NET Terms & Concepts • Dr. Aman Chauhan • 2023 LACNETS Patient Conference Watch "NETS 101: Overview of NET Terms & Concepts" with Dr. Aman Chauhan. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit, LACNETS.org. Play Video Play Video 15:22 05. NET Surgery: Making Decisions & Preparing for Surgery (Dr. Clarke) - 2022 LACNETS Conference Dr. Callisia Clarke addresses surgery for neuroendocrine cancer including decision-making & preparing for surgery. Presenter: Callisia Clarke, MD Surgical Oncologist Medical College of WI 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 07:50 Patient Story: NET Patient shares about the first year of her NET journey (LACNETS) NET Patient Laurie shares about the first year of her NET journey. November 7, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 01:37:42 LACNETS Webinar: "Sequencing of Neuroendocrine Tumor Treatments" with Dr. Eric Liu LACNETS webinar - “Sequencing of Neuroendocrine Tumor Treatments" Friday, May 24th, 2020 SPEAKER: Dr. Eric Liu, General Surgeon & Neuroendocrine Specialist Rocky Mountain Cancer Center Learn more here: www.LACNETS.org Audio/Video - www.TVPlive.com Play Video Play Video 01:04:39 LACNETS - NET VITALS Webinar - September 6th, 2018 Download NET VITALS here: www.lacnets.org/netvitals NET VITALS Webinar - Question Timing Guide: Introductions: Start - 10:25 Q1. My neuroendocrine tumor (NET) was found: 10:41 Q2. I am a neuroendocrine tumor (NET) patient and my primary (origin) tumor is: 11:05 Q3. My NET has spread (metastasized) to: 11:57 Q4. My Ki-67 index is 14:20 Record-keeping: 14:38 Pathology report example: 17:25 Q5. My neuroendocrine tumor is: 18:15 Q6. My neuroendocrine tumor is: 22:17 Q7. I have symptoms: 23:50 Q8. I have had symptoms for ____ years (if applicable). 23:50 Q9. I have had the following types of imaging, and possess the disk and/or report: 29:30 Q10. I have had the following labs, and possess the report (if applicable): Indicate if abnormal. 32:55 Q11. Surgery to remove primary tumor(s): 38:45 Q12. Surgery to remove metastatic tumor(s): 39:05 Q13. Other surgery 39:40 Q14. Liver-Directed treatment: 40:10 Q15. Somatostatin Analogs (SSA) & Others: 42:48 Q16. Chemotherapy / Biologically-Targeted / Immunotherapy, including Clinical Trials/ PRRT (Peptide Receptor Radionuclide Therapy, i.e. Lutathera®): 44:03 Q17. I am diabetic: 47:50 Q18. ALLERGIES (Medications/Food): 48:05 Q19. FAMILY HISTORY (Specify cancer and/or rare diseases): 48:20 Q20. I have had Genetic Testing: 48:37 Q21. MEDICATIONS/SUPPLEMENTS (including vitamins, digestive enzymes): 49:01 Q22. CURRENT PHYSICIAN(S) & MEDICAL TEAM 49:29 Q23. SOCIAL SUPPORT 50:13 Q&A with the NET VITALS Team 52:23 What is NET Vitals? LACNETS created NET VITALS as a quick snapshot of the most important questions for patients and healthcare professionals to know about neuroendocrine cancer. NET VITALS is a 20-question tool designed to highlight the vitals of NET cancer, all in one document. This allows the physician and patient to more easily communicate with all of the basics in one place. Webinar Leaders: Giovanna Joyce Imbesi, MBA, Executive Director, LACNETS Lisa Yen, NP, NBC-HWC, Program Director, LACNETS Dan Li, MD, Medical Oncologist, City of Hope Josh Mailman, MBA, President, NorCal CarciNET Learn more here: https://www.lacnets.org/lacnets-blog/netvitals Play Video Play Video 20:22 "Qué esperar de una consulta de expertos de NET" con Dr. Heloisa Soares (LACNETS) "Qué esperar de una consulta de expertos de NET" con Dr. Heloisa Soares (LACNETS) Presentadora: Heloisa Soares, MD, PhD Medical Oncologist; Huntsman Cancer Institute Para obtener más recursos en español, visite www.LACNETS.org. Play Video Play Video 30:23 04. What to Expect with a NET Expert Consultation (Dr. Soares) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Heloisa Soares, MD, PhD Medical Oncologist Huntsman Cancer Institute This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 42:50 Finding a NET Expert + Surgery for NETs - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: LACNETS Conference Welcome (0:00 - 5:44) Lindsey Jeu De Vine, Director of Communications, LACNETS Lisa Yen, NBC-HWC, Program Director, LACNETS "Finding a NET Expert" (5:44 - 22:25) Cindy Lovelace , Executive Director Healing NET Foundation "Surgery for NETs" (22:25 - end of video) Alexandra Gangi, MD , Surgical Oncology Cedars-Sinai Medical Center For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 43:19 "NETs 101" with Medical Oncologist Dr. Sandy Kotiah of Mercy Medical Medical oncologist and NET expert Dr. Kotiah covers what to expect during your first visit with your medical oncologist – plus labs, scans, and prognosis. Speaker: Sandy D. Kotiah, MD Medical Oncologist, Hematologist Mercy Medical To learn more about LACNETS, visit www.LACNETS.org. < Back to Topics Next Topic >

NET Quiz TEST YOUR NET KNOWLEDGE QUIZ #31 - UNDERSTANDING FATIGUE & NETS Here’s a short quiz based on NETRF's NETWise Podcast Episode 30: "Understanding Fatigue & NETs." TAKE THE QUIZ QUIZ #30 - MERKEL CELL NETS Here’s a short quiz based on NETRF's NETWise Podcast Episode 29: "Merkel Cell NETs." TAKE THE QUIZ QUIZ #29 - NETS & RACE Here’s a short quiz based on NETRF's NETWise Podcast Episode 27: "NETs & Race." TAKE THE QUIZ QUIZ #28 - GYNECOLOGIC NETS Here’s a short quiz based on NETRF's NETWise Podcast Episode 24: "Gynecologic NETs." TAKE THE QUIZ QUIZ #27 - PARENTING WITH NETS Here’s a short quiz based on NETRF's NETWise Podcast Episode 23: "Parenting With NETs." TAKE THE QUIZ QUIZ #26 - ADJUSTING TO & NAVIGATING THE NEW NORMAL Here’s a short quiz based on NETRF's NETWise Podcast Episode 21: "Adjusting to the New Normal" and Episode 22: "Navigating the New Normal." TAKE THE QUIZ QUIZ #25 - NET RESEARCH (PART 2) Here’s a short quiz based on NETRF's NETWise Podcast Episode 20: “NET Research – Part Two.” TAKE THE QUIZ QUIZ #24 - NET RESEARCH (PART 1) Here’s a six question quiz based on NETRF's NETWise Podcast Episode 19: “NET Research – Part One.” TAKE THE QUIZ QUIZ #23 - HIGH-GRADE NETS AND NECS Here’s a five question quiz based on NETRF's NETWise Podcast Episode 18: “High-Grade NETs and NECs.” TAKE THE QUIZ QUIZ #22 - LIVER NETS Here’s a five question quiz based on NETRF's NETWise Podcast Episode 17: "Focus on Liver NETs." TAKE THE QUIZ QUIZ #21 - NETS AND NUTRITION Here’s a five question quiz based on NETRF's NETWise Podcast Episode 16: “NETs and Nutrition.” TAKE THE QUIZ QUIZ #20 - SUPPORTIVE CARE FOR THE MIND, BODY, AND SOUL Here’s a five question quiz based on NETRF's NETWise Podcast Episode 15: “Supportive Care for the Mind, Body, and Soul.” TAKE THE QUIZ QUIZ #19 - PHEOS & PARAS Here’s a six question quiz based on NETRF's NETWise Podcast Episode 14: “Pheos & Paras.” TAKE THE QUIZ QUIZ #18 - NETS AND GENETIC SCREENING Here’s a six question quiz based on NETRF's NETWise Podcast Episode 13: “NETs and Genetic Screening.” TAKE THE QUIZ QUIZ #17 - THE IMPORTANCE OF CAREGIVING Here’s a five question quiz based on NETRF's NETWise Podcast Episode 12: "The Importance of Caregiving." LACNETS’ Program Director and a NET caregiver, Lisa Yen, is a guest on this episode! TAKE THE QUIZ QUIZ #16 - AYA (ADOLESCENTS & YOUNG ADULTS) AND NETS Here’s a four question quiz based on NETRF'w NETWise episode 11, "AYA (Adolescents and Young Adults) and NETs." TAKE THE QUIZ QUIZ #15 - SMALL BOWEL NETS Here’s a five question quiz based on NETRF'w NETWise special episode, "Small Bowel NETs.” TAKE THE QUIZ QUIZ #14 - PANCREATIC NETS Here’s a seven question quiz based on NETRF's NETWise episode #10, “Pancreatic NETs.” TAKE THE QUIZ QUIZ #13 - LUNG NETS Here’s a six question quiz based on NETRF's NETWise special episode, “Lung NETs.” TAKE THE QUIZ QUIZ #12 - CLINICAL TRIALS Here’s a six question quiz based on NETRF's NETWise podcast episode, “Clinical Trials.” TAKE THE QUIZ QUIZ #11 - MANAGING SYMPTOMS OF NETS Here’s a seven question quiz based on NETRF's NETWise podcast episode, “Managing Symptoms of NETs.” TAKE THE QUIZ QUIZ #10 - MEDICAL MANAGEMENT OF NETS Here’s a seven question quiz based on NETRF's NETWise podcast episode, “Medical Management of NETs: Understanding SSAs, Chemotherapy, and Targeted Therapy” . TAKE THE QUIZ QUIZ #9 - NUCLEAR MEDICINE FOR NETS: WHAT IS PRRT? Here’s a quick six question quiz based on NETRF's NETWise podcast episode, “Nuclear Medicine for NETs: What is PRRT?” TAKE THE QUIZ QUIZ #8 - COVID-19 AND NETS Here’s a quick seven question quiz based on NETRF's NETWise podcast episode, “COVID-19 and NETs.” TAKE THE QUIZ QUIZ #7 - SURGERY AND INTERVENTIONAL RADIOLOGY FOR NETS Here’s a six question quiz based on the NETRF's NETWise podcast episode #3, “Surgery and Interventional Radiology for NETs.” TAKE THE QUIZ QUIZ #6 - IMAGING, TESTING, & BUILDING A CARE TEAM (PART 2) Here’s a six question based on NETRF's NETWise podcast episode #2: “Imaging, Testing, and Building a Care Team.” TAKE THE QUIZ QUIZ #5 - IMAGING, TESTING, & BUILDING A CARE TEAM (PART 1) Here’s a quick five question quiz based on NETRF's NETWise podcast episode #2: “Imaging, Testing, and Building a Care Team.” TAKE THE QUIZ QUIZ #4 - WHAT YOU NEED TO KNOW ABOUT NETS We put together a quick quiz based off of the first episode of NETRF’s NETWise podcast, “What You Need to Know About NETs. ” TAKE THE QUIZ QUIZ #3 - REVIEW NET BASICS Review your NET basics by taking this five question quiz! This quiz is just a fun way to learn! If you get it wrong, don't stress! Now you know the correct answer! TAKE THE QUIZ QUIZ #2 - LEARN TO SPEAK NET LACNETS put together a quick five question quiz to help you learn to speak NET! TAKE THE QUIZ QUIZ #1 - TEST YOUR KNOWLEDGE ON NET In honor of Rare Disease Day 2019, LACNETS put together a quick four-question quiz to test your knowledge on neuroendocrine cancer! TAKE THE QUIZ

Educational Events < Back to Topics Play Video Play Video 01:33:05 Novel Targeted Therapies in Neuroendocrine Cancers • 2026 NCF Event • Mar 9, 2026 Some Topics Covered: Neuroendocrine, NET, NEC, High-grade Clinical trials, PRRT, RLT, Antibody Drug Conjugate (ADC), DLL3 ABOUT Learn from a discussion of targeted therapies in neuroendocrine cancer, one of the fastest-growing areas of NET treatment. Unlike traditional chemotherapy, targeted therapies focus on specific pathways or features of cancer cells. Understanding how these treatments work can help patients feel more confident and informed when discussing options with their care team. In this session, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explores novel, innovative targeted treatments used or being studied in NETs, such as DLL3 and antibody–drug conjugates (ADCs). Dr. Thummalapalli will explain what these therapies are, how they work, and why they are becoming increasingly important in NET care. Whether you’re newly diagnosed or considering later-line treatments, this webinar will help you better understand the evolving landscape of targeted therapy and what it may mean for your care. Visit the event page at https://www.ncf.net/events/mar2026 Play Video Play Video 01:29:26 The Latest in Neuroendocrine Cancer Clinical Trials • 2026 NCF Event • Feb 20, 2026 Topics Covered: Neuroendocrine, NET, clinical trials, PRRT, RLT, neoadjuvant trials, adjuvant trials, metastatic NET, symptom control ABOUT Join us for an overview of the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, a medical oncologist and physician-scientist at the Huntsman Cancer Institute (HCI) in Salt Lake City. Dr. Soares will walk through key neuroendocrine cancer clinical trials including what they are studying, what makes them exciting, and how they may shape future treatment options. She will also explain why clinical trials matter, how they benefit patients, and what to consider when exploring whether a trial might be right for you. Whether you’re a patient, caregiver, or simply trying to stay informed, this webinar will provide clear, practical insights to help you better understand emerging research and what it means for the neuroendocrine cancer community. The presentation focuses on current NET clinical trials. For information on NEC clinical trials, go to our high grade resources page: https://www.ncf.net/high-grade-nen-resources. Visit the event page at https://www.ncf.net/events/feb2026 Play Video Play Video 01:31:30 The Latest on Immunotherapy for Neuroendocrine Cancer • 2025 NCF Event • Dec 11, 2025 Immunotherapy is an exciting and rapidly advancing area in the treatment of neuroendocrine cancer. Join Dr. Aman Chauhan, Medical Oncologist at the University of Miami Sylvester Cancer Center, as he discusses the latest developments in immunotherapy for neuroendocrine cancer. This webinar will cover current standard-of-care treatments as well as cutting-edge clinical trials involving DLL3-targeted therapies, oncolytic viruses, CAR T-cell therapy, and combination approaches. Whether you’re newly diagnosed or exploring new treatment options, this session will help you better understand the evolving landscape of immunotherapy in neuroendocrine cancer. Aman Chauhan, MD Medical Oncologist University of Miami Sylvester Cancer Center Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer Institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is the national principal investigator on several investigator-initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. Visit https://www.ncf.net/events/dec2025 for more information. Play Video Play Video 01:27:39 Understanding Alpha & The Evolving PRRT Landscape • Dr. Grewal • 2025 NCF Event • September 22, 2025 The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. For more information, visit https://www.ncf.net/events/sep2025. Play Video Play Video 01:25:23 Nutrition & Diet Considerations for NETs • 2025 NCF Event • August 26, 2025 Nutrition can play a key role in living well with neuroendocrine cancer (neuroendocrine tumors or NETs). Join NET dietitian Meghan Laszlo for an informative session on nutrition and diet considerations for people living with neuroendocrine cancer. She will cover key topics including the use of pancreatic enzymes, managing hyperglycemia, navigating special diets, and understanding supplements. Whether you're newly diagnosed or further along in your journey, this webinar offers practical guidance to help you make informed nutrition choices that support your health and quality of life. For more information, visit ncf.net. Play Video Play Video 01:16:25 Living with NET: The Patient Perspective • 2025 NCF Event • July 10, 2025 Patients share their experiences on topics, including decision-making, coping strategies, lessons learned, challenges, and navigating relationships while living with neuroendocrine cancer. Hear about their personal journeys—filled with resilience, realities, and hope, that offer powerful insight into what it's like living with neuroendocrine cancer. Visit NCF.net/July2025 for more information. Play Video Play Video 01:33:27 "Evolving Management of Carcinoid Heart Disease" • Prashanth Venkatesh, MD, FACC • April 29, 2025 Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. For more information and resources, visit NCF.net. Play Video Play Video 01:30:51 "Understanding Treatments for NETs and Rationale for Sequencing of Therapy" • Dr. Wolin • Apr 1, 25 Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Join us for an insightful presentation and live question and answer session. Learn more at https://www.ncf.net/events/apr2025 Play Video Play Video 01:49:57 "PRRT Nurse's Perspective: What to Expect with PRRT" • Linda Gardner, MSN, RN, VA-BC • Mar 7, 2025 Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. Learn more at https://www.ncf.net/events/mar2025 Play Video Play Video 01:28:12 "Deciphering Genetics & Genomics in Neuroendocrine Cancers" • Dr. Perez • Feb 7, 25 Learn the latest in genetics and genomics for neuroendocrine cancers from medical oncologist Dr. Kimberly Perez from Dana Farber Cancer Institute (DFCI) in Boston, Massachusetts. Dr. Perez has expertise in hereditary cancer syndromes and deciphers the topics of genetics and genomics. Learn more at LACNETS.org. Play Video Play Video 01:33:06 "Understanding GI NETs Found on Endoscopy: Gastric, Duodenal, Colon & Rectal" • Dr. Metz •Jan 28, 25 Learn from renowned Neuroendocrinologist Dr. David Metz, who discusses neuroendocrine tumors (NETs) found on endoscopy, including gastric, duodenal, colon and rectal NETs. Dr. Metz discusses which NETs can be found on endoscopies and how they are managed and treated. For more information, visit LACNETS.org. Play Video Play Video 01:28:05 "Large Cell Neuroendocrine Carcinoma & Small Cell Lung Cancer" • Session B • LACNETS • Dec 10, 2024 This is a 2-session comprehensive guide to lung neuroendocrine cancers. Session A covers Typical Carcinoids and Atypical Carcinoids. Watch Session A here: https://youtu.be/owZRDf3ISM4 Session B covers Large Cell Neuroendocrine Carcinoma and Small Cell Lung Cancer. ABOUT AMAN CHAUHAN, M.D. Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. For more information, visit LACNETS.org. Play Video Play Video 01:33:36 "Typical Carcinoid & Atypical Carcinoid" • Session A • LACNETS Event • Dec 10, 2024 This is a 2-session comprehensive guide to lung neuroendocrine cancers. Session A covers Typical Carcinoids and Atypical Carcinoids. Session B covers Large Cell Neuroendocrine Carcinoma and Small Cell Lung Cancer. Watch Session B here: https://youtu.be/LxXdXMKpaCo ABOUT AMAN CHAUHAN, M.D. Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. For more information, visit LACNETS.org. Play Video Play Video 01:26:11 "Palliative Care for Neuroendocrine Cancer" Dr. Chandana Banerjee • 2024 #LACNETS Educational Event Learn about Palliative Care: what it is, what it is not, and how it may help those affected by neuroendocrine cancer. Dr. Chandana Banerjee, a palliative care and hospice specialist from the City of Hope Cancer Center in Los Angeles, demystifies these topics. Visit LACNETS.org for more information. Play Video Play Video 01:35:06 "Evolving Management of NET Liver Metastases" Dr. Gagandeep Singh • 2024 #LACNETS Educational Event Join us to hear renowned liver and pancreas surgeon Dr. Gagandeep “Gaugs” Singh discuss the evolving algorithms in the management of NET liver metastases. Dr. Singh, Chief of Surgical Oncology at City of Hope® Cancer Center in Phoenix, asks the question of whether it is prudent to be aggressive surgically or if it is all about timing and strategy. For more information, visit LACNETS.org. Play Video Play Video 01:27:16 "2024 Updates on Clinical Trials in Neuroendocrine Tumors" • 2024 LACNETS Event • April 25, 2024 Join us to learn about the latest in clinical trials for neuroendocrine tumors with NET expert Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah. For more information about Clinical Trials, visit https://www.lacnets.org/clinical-trials. For more information, visit LACNETS.org. Play Video Play Video 01:18:47 "TKIs: Tyrosine Kinase Inhibitors & Neuroendocrine Tumors" • 2024 LACNETS Event • March 29, 2024 Learn about Tyrosine Kinase Inhibitors (TKIs), what they are and how they work with NET expert Dr. Jennifer Chan. Dr. Chan is the Vice President of the North American Neuroendocrine Tumor Society (NANETS) and the principal investigator of the CABINET trial. Hear the positive findings from that TKI study using Cabozantinib. She will discuss the latest in TKI treatments and how they may be a possible treatment option for many NET patients. For more information, visit lacnets.org. Play Video Play Video 01:29:36 "Carcinoid Heart Disease" • 2024 LACNETS Event • Feb 14, 2024 Learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis, at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. Visit LACNETS.org for more information. Play Video Play Video 01:12:47 "PRRT: What We Know, Special Considerations & Clinical Trials" with Dr. Strosberg • Jan 11, 2024 Learn the latest on PRRT with NET expert Dr. Jonathan Strosberg. Dr Strosberg was the principal investigator of the NETTER-1 study which led to the FDA approval of Lutathera and has authored numerous articles on PRRT. He will discuss the latest in PRRT, including special considerations and current clinical trials. Visit LACNETS.org for more information. Play Video Play Video 01:19:50 "Minimally Invasive Treatments for Neuroendocrine Liver Metastases" • Dr. Yilun Koethe • Dec 9, 2023 "Minimally Invasive Treatments for Neuroendocrine Liver Metastases" with Dr. Yilun Koethe, Interventional Radiologist, TRG Imaging. Learn more about minimally invasive liver directed therapies targeting liver metastases with interventional radiologist Dr. Koethe. She discusses ablations including the recently approved histotripsy and embolizations including bland, chemo and radioembolization. ~ Visit LACNETS.org for more information. Play Video Play Video 01:33:48 LACNETS • "Symptom Management" with Dr. David Metz • Oct 2023 Join LACNETS to hear Neuroendocrinologist, Dr. David Metz from University of Pennsylvania discuss symptom management. The presentation will cover carcinoid syndrome, pancreatic enzymes, bile acid secretion, and short bowel syndrome. He will explain current treatments, supplements, and diets that might be helpful to control NET-related symptoms. For more information, visit LACNETS.org. Play Video Play Video 01:30:11 LACNETS • "Navigating Clinical Trials: Expectations vs. Realities" with Taymeyah Al-Toubah •Aug 2023 Join LACNETS to hear Taymeyah Al-Toubah, MPH, Senior Research Project Manager at the Neuroendocrine Tumor Program of Moffitt Cancer Center. About Our Speaker: Taymeyah Al-Toubah, MPH Senior Research Project Manager Neuroendocrine Tumor Program at Moffitt Cancer Center, Tampa, FL Taymeyah Al-Toubah is a clinical researcher, currently at Moffitt Cancer Center, who has been in the research field for 10 years. She began her career in 2013 while obtaining her bachelor’s degrees in biomedical sciences and psychology, working in pediatric and neonatal research at Johns Hopkins All Children’s Hospital. In 2016, she shifted her career focus to oncology, beginning with phase I trials and working in all solid tumors. She completed her Master of Public Health in Epidemiology in 2017 and focused her graduate thesis on neuroendocrine tumors. In 2018, she switched departments to focus exclusively on NETs. From 2018 – 2023, she was the primary NET coordinator in the GI department, managing all clinical trials while leading the GI team, managing the NET clinic coordination amongst the ancillary departments, and working on all retrospective and non-interventional NET research. She has worked on protocol development, database analysis, and manuscript writing, resulting in over 30 published manuscripts and presented her research at several national and international oncology and NET conferences, with oral abstracts at several ENETS and NANETS conferences. In April 2023, she formally transitioned to a new position as a project manager of the NET program, where she will continue to mentor new coordinators while working on protocol development and writing, manuscript writing, non-interventional clinical trials, and retrospective NET research. One of her first major projects will be to curate and develop a master database of all NET patients seen at her institution that will provide the basis for all future NET research to be published at Moffitt. She is currently on the board of one of the first NET patient advocacy groups in Florida (FLaNET Carcinoid Community), which kicked off alongside the Tampa Regional NANETS meeting in November 2022. She is an active member of NANETS on the Continuing Education and Symposium Planning committees. She plans to dedicate the remainder of her career to this disease and community. Her ultimate plan is to attend medical school, specialize in medical oncology, and continue to serve the academic NET community and patient base as a physician and clinical investigator. For more information, visit LACNETS.org. Play Video Play Video 01:25:46 "Surgery: The What, Where & When" with Dr. Eric Liu • LACNETS • July 2023 Join LACNETS to hear NET expert Dr. Eric Liu of Rocky Mountain Cancer Centers discuss “Surgery: The What, Where & When.” To learn more, visit LACNETS.org. Play Video Play Video 01:04:08 LACNETS • "High Grade Neuroendocrine Neoplasms (NEN)" with Dr. Jason Starr • May 2023 Join LACNETS on May 4th for an educational event dedicated to high grade neuroendocrine neoplasms (NENs). Medical oncologist Dr. Jason Starr from Mayo Clinic in Jacksonville, Florida, will discuss the management and treatment of high grade NENs, including the latest updates and clinical trials. For more information, visit LACNETS.org. Play Video Play Video 01:28:20 LACNETS • "What's New in PRRT" with Dr. Amir Iravani • Apr 2023 Join Dr. Amir Iravani, a Nuclear Medicine Physician and Theranostics Director at Fred Hutchinson Cancer Center, to hear the latest on Peptide Receptor Radionuclide Therapy (PRRT). Better understand the difference between beta and alpha PRRT, current trials and updates on PRRT for Lung NET, adolescents and dosimetry. For more information, visit LACNETS.org. Play Video Play Video 01:32:12 LACNETS • "Update on NET Clinical Trials" with Dr. Heloisa Soares • Mar 2023 Join us for an "Update on NET Clinical Trials" with special guest Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah, to hear the latest in NET clinical trials. Visit LACNETS.org/Mar2023 for more information. Play Video Play Video 01:29:21 LACNETS • "Genetics of NET: Do I Need Genetic Testing?" with Samantha Greenberg • Feb 2023 Do I need genetic testing? Do my family members need to be tested? What does genetic testing entail? What genetic mutations are possible and what does it mean for my family if I carry a mutation? Join Genetic Counselor Samantha Greenberg of the University of Texas, Southwestern, for a discussion about genetic testing for NETs. For important information and resources about this topic, visit LACNETS.org/Feb2023. To learn more about LACNETS, visit LACNETS.org. Play Video Play Video 01:34:45 LACNETS • "Novel Translational Research for Metastatic NET Patients at the NCI" • Jan 2023 Join LACNETS for this special educational event. What if you could both undergo surgery for your metastatic disease and also donate your liver tumor to find a cure for NET? Learn how you can contribute to NET research. The NET team at the National Cancer Institute (NCI) will give us a behind-the-scenes look at their innovative NET research. Be inspired by their hard work and dedication to the NET community. For more information, visit LACNETS.org. Play Video Play Video 01:42:02 "Focus on Pheochromocytoma and Paraganglioma" - Jan 2023 LACNETS Educational Event Join LACNETS for a Rebroadcast of the unique webinar presentation of three pheochromocytoma and paraganglioma (PPGL) cases and an engaging panel discussion with experts Dr. Jaydira Del Rivero, Dr. Erik Mittra, and Dr. Karel Pacak. (Original broadcast on Wednesday, January 11, 2023) Play Video Play Video 01:49:16 LACNETS • December 2022 Monthly Webinar - "2022: YEAR IN REVIEW" with Dr. Halfdanarson Join LACNETS and medical oncologist Dr. Thorvardur Halfdanarson of Mayo Clinic for the live webinar, “2022: Year in Review” on Friday, December 9 at 11 am Pacific Time. Have non-case specific questions for Dr. Halfdanarson? There will be a live Q&A following his presentation. To submit your questions, go to www.slido.com/LACNETS12. To learn more about LACNETS, visit www.LACNETS.org. Load More < Back to Topics Next Topic >

Xermelo Resources https://www.xermelo.com/ Talk to a NET nurse about carcinoid syndrome diarrhea. Go to www.enrollxermelo.com . Download the TerSera Nursing Support Program brochure Download the Xermelo Patient Brochure

Resources from our Partners AAA resources: Facts about PRRT, patient brochures, and contact information Click here for AAA Resources Ipsen resources: Patient brochures, copay information packet, SOMATULINE® DEPOT prescribing information packet, and contact information Click here for Ipsen Resources TerSera resources: Patient brochures, nurses patient brochure, nutrition guide & recipes for Carcinoid Syndrome, and contact information Click here for TerSera Resources RayzeBio resources: Clinical trial information, and contact information Click here for RayzeBio Resources Lantheus resources: Azedra patient brochure, Azedra Service Connection Patient Services brochure, and Azedra and Lantheus websites Click here for Lantheus Resources Crinetics Resources: Information about Patient Insights Program, Patient Leadership Council, and clinical trial information Click here for Crinetics Resources DISCLAIMER: These resources are for informational and educational purposes only and are not substitute for professional medical advice. This information is not intended to provide a medical professional’s opinion or advice. You are advised to seek appropriate licensed medical professional help. Please do not delay treatment based on this information. Talk to your medical team if you have any questions or concerns about your individual care or treatment.

Save the Date - June 17, 2023 Watch the 2023 LACNETS Neuroendocrine Tumor Patient Conference 2023 LACNETS Neuroendocrine Tumor Patient Conference 2023 LACNETS Neuroendocrine Tumor Patient Conference Play Video Share Whole Channel This Video Facebook Twitter Pinterest Tumblr Copy Link Link Copied Now Playing Welcome & Introduction • 2023 LACNETS Neuroendocrine Tumor Patient Conference • June 17, 2023 13:08 Play Video Now Playing NETS 101: Overview of NET Terms & Concepts • Dr. Aman Chauhan • 2023 LACNETS Patient Conference 21:51 Play Video Now Playing A Conversation with Three NET Surgeons • Dr. Clarke, Dr. Gangi & Dr. Anaya • 2023 LACNETS Conference 27:33 Play Video Join us virtually for our biggest event of the year to hear from 12 NET experts from North America. Click Here to Read Speaker Bios Visit Sponsor Booths 2023 Conference Sponsors VISIT SPONSOR BOOTHS IPSEN Booth TerSera Booth Curium Booth AAA Booth Crinetics Booth Camurus Booth The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

Supporters of the Neuroendocrine Cancer Foundation Thanks to our Sponsors NCF partners with sponsors to connect patients and caregivers to the most up-to-date resources, financial help, and access to treatments and trials. SPONSOR THE NEUROENDOCRINE CANCER FOUNDATION Sponsors and donors make our work possible. Contact us to learn how you can support us. First Name Last Name Email Send Thanks for submitting!

Imaging Resources PODCAST Confused about scans? NET expert Dr. Gary Ulaner answers the top 10 questions about imaging for NETs. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner explains different scans used in NET imaging including functional imaging scans such as Gallium-68 DOTATATE, Copper-64 DOTATATE, and FDG PET scans and anatomical scans such as MRI and CT scans. He addresses common questions about radiation safety, contrasts, and SUV. Listen Here EDUCATIONAL WEBINARS NET Imaging NET Imaging Play Video Share Whole Channel This Video Facebook Twitter Pinterest Tumblr Copy Link Link Copied Now Playing 4. What Matters About Scans? • Nadine Mallak, MD • @NCFCancer 14:53 Play Video Now Playing "Understanding NET Scans" with Dr. Nadine Mallak • 2024 LACNETS NET Patient Conference 23:47 Play Video Now Playing The Latest in NET Imaging • Dr. Nadine Mallak • 2023 LACNETS Patient Education Conference 19:08 Play Video ADDITIONAL IMAGING RESOURCES Detectnet Patient Brochure by Curium Detectnet is used with a PET scan to help diagnose possible NETs A Guide to Understanding Neuroendocrine Tumors (NETs) and the Role of Imaging NANETS NET GUIDELINES 2017 (Joint with SNMMI) Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

Our Vision The Vision initiative is in memory of Giovanna Joyce Imbesi, the late founder of LACNETS (now Neuroendocrine Cancer Foundation), whose vision was to empower neuroendocrine cancer patients and caregivers by providing a healing exchange of educational resources. The Neuroendocrine Cancer Foundation provides education, advocacy, and support through its programs, which play a key role in treatment decisions. Giovanna left behind a profound legacy. The Neuroendocrine Cancer Foundation has a great responsibility to help sustain this organization and keep her vision alive due to the impact she had on the neuroendocrine cancer community. The Neuroendocrine Cancer Foundation invites you to participate in our vision initiative supporting neuroendocrine cancer patients and their loved ones. Be a part of the healing. Make a difference today! Large or small, every gift matters and is genuinely appreciated. Your generous contribution will go towards funding the Neuroendocrine Cancer Foundation's greatest needs, such as the production of our educational webinars, podcasts, and conferences. Donate to the Neuroendocrine Cancer Foundation to carry on Giovanna's legacy and vision. Thanks to the generosity of a few committed donors, your gift will be matched dollar for dollar. Help Fund the Vision Watch the tribute video honoring Giovanna Joyce Imbesi by Rich Tamayo, Emmy Winning Video Producer & a friend In Loving Memory Giovanna Joyce Imbesi Our founder, hero & inspiration to live life fully… Giovanna Joyce Imbesi, LACNETS founder, was a patient advocate, pianist, and composer based in Los Angeles. She lived fully with neuroendocrine cancer for 14 years and served as a model of compassion, love and kindness. In 2005, after several years of misdiagnosis, Giovanna was diagnosed with metastatic small bowel neuroendocrine cancer. She understood that those with a rare cancer may feel isolated, and sharing similar experiences may lessen the fear of the unknown and offer comfort. It became her mission to help others in the NET community. Her vision was to create a community for a healing exchange of educational resources and emotional support for all affected by neuroendocrine cancer. Against all odds, Giovanna went on to receive an MBA from UCLA Anderson School of Management with the sole intent of launching LACNETS. In 2012, she founded the non-profit GeneratePossibility and the Los Angeles Carcinoid Neuroendocrine Tumor Society (LACNETS) program. Giovanna's physician, Dr. Edward Wolin, was the inaugural speaker for the first LACNETS' patient education meeting. Through LACNETS, Giovanna's aspiration was to create a more "NET-fluent" world. She wanted to change the narrative from associating NET with famous people who die from the disease to raising awareness of the more than 180,000 people who live with the disease. Giovanna wrote, "Each one of us has the ability to help change those numbers in our own community. There are more opportunities to share more about NET and add one more person to the extended global family of NET awareness." Giovanna helped create tools, such as NET VITALS, to improve communication between patients and physicians. She believed that increased awareness equates to more research, which leads to improved treatments and patient outcomes. Giovanna received the 2016 Monica Warner Advocacy Award, as well as the 2019 Cedars-Sinai Patient Leadership Award , for her inspiring work in patient advocacy. Giovanna Joyce Imbesi passed away peacefully on November 24th, 2019. On her last day, Giovanna said with great pride that her greatest legacy was LACNETS. She felt blessed by this community. Giovanna often said, "Aging is a privilege." She celebrated life and connectedness. She believed in practicing gratitude, even appreciating the difficult times. She was grateful for the thousands of neuroendocrine tumor physicians, researchers and healthcare providers who work on the behalf of NET patients every day. The Neuroendocrine Cancer Foundation works daily to honor Giovanna's vision by serving the NET community she established and helping others to live life richly and fully with NET like she did. Participate in the Vision GENERATE POSSIBILITY For Giovanna, music was medicine. Her musical compositions can be heard on "Short Stories - piano music for healing, meditation & relaxation" recorded while in recovery from neuroendocrine cancer surgery. These pieces were inspired by her belief in the healing power of music as a vital element of our well-being. She frequently contributed music to NET causes. A frequent speaker on living with neuroendocrine cancer and the healing power of music, Giovanna was featured as one of six leaders in Integrative Cancer Care at the 2018 Symington Public Forum at Commonweal. We hope that Giovanna's song and her own words, "Give Me Peace," bring some comfort and peace. I’ll always be grateful for Giovanna and her work through LACNETS (now Neuroendocrine Cancer Foundation). The information I learned and connections I made through the educational meetings changed the course of my medical care and helped me to get back to a place where I could enjoy life. — Tom, NET Patient

Privacy Policy Last Updated: March 23, 2026 Objective This policy applies to all personal data processing carried out by the Company and aims to inform the user about the way in which the Company processes personal data (including details of the type of personal data collected and the purpose of processing) and regarding the rights of the user in relation to their personal data. Contact Information In case a user has any questions about the Privacy Policy or would like to establish communication, the user can contact the Company through the following means: Address: 2108 N ST # 9937 Sacramento, CA 95816 Phone Number: (310) 800-2999 Email Address: info@ncf.net In addition, information about the officer in charge of processing your personal data is listed below: Company Name: Neuroendocrine Cancer Foundation referred to in this document as “Company” Identity of the Controller: Neuroendocrine Cancer Foundation Address: Email Address: info@ncf.net referred to in this document as “Email Address” Approval Your use of the Site constitutes your acknowledgment and approval of the Company's Privacy Policy and the Company’s Terms and Conditions, if any. Categories of Personal Information We Collect About You In compliance with current regulations on the protection of personal data and depending on your interaction with us, we may collect the following categories of personal information about you directly from you, from third parties, and automatically through your use of our Site. Identifiers, such as your name, postal address, telephone number, date of birth, IP address, unique online identifier, or similar identifier. Protected classifications, such as age and gender. Payment information, such as your financial account information, credit card number, debit card number, or other payment card information. Commercial Information, such as records of products or services purchased or obtained, membership records, and records of gifts. Professional information, such as the name of your employer and business title. Internet or other electronic network activity, such as your browser type and operating system; web pages you view, links you click, search history on the site, and other information regarding your interaction with an internet website, email, newsletter, or advertisement; the length of time you visit our site; and the referring URL, or the webpage that led you to our site. Geolocation data, as defined under applicable law. Inferences, such as inferences drawn to create a profile reflecting your preferences, characteristics, psychological trends, predispositions, behavior, attitudes, intelligence, abilities, or aptitudes. Sensitive personal information, as defined under applicable law, such as your precise geolocation data and financial account information. Information We Collect Directly From You. We collect personal information directly from you when you use our Service. If you sign up to receive information or services from us or if you register for an account on our site, we may collect your contact information (e.g., name, home address, telephone number, or email address) and account login credentials. If you contact us, we may collect your contact information, as well as the contents of a message or attachments that you may send to us, and other information that you choose to provide. Information We Collect From Other Sources. We may collect personal information from our parent, affiliate, and other related entities, as well as from third parties that perform functions on our behalf, such as our advertising and analytics partners. When you sign in to our Service using a social media account, you give permission to the social media platform to share your personal information with us. Information We Collect Automatically. We, and our third-party business partners, automatically collect personal information when you use our Service using cookies, pixel tags, clear GIFs, or similar technologies. This may include information such as your IP address and the types of personal information described above as “Internet or other electronic network activity.” This may also include information about your location if you give us permission to do so (“Geolocation Data”) by setting your device to allow for location tracking/data or by opting into browser prompts that ask for location tracking. You can enable or disable location services when you use our Service at any time, through your device settings. Please review our section below on Cookies for additional information regarding our use of cookies and related technologies. How We Use Your Information Depending on your interaction with us, we may use the categories of personal information described above for the following business and commercial purposes: To provide our Service and fulfill your requests. We use your information to provide and maintain our Service, to process and fulfill your requests, to communicate with you about your use of our Service or changes to our Service, to respond to your inquiries, and for other customer service and business administration purposes. To improve our Service. We use your information to understand and analyze our user base and how you use the Service, to improve and enhance the Service, and to develop new products, services, features, and functionality. Identification and authentication purposes. We may use your information for identification and authentication purposes. For example, when you enter your account login ID and password to enter one of our registration or login portals, we use your login credentials to authenticate your identity. Personalization. We use your information to tailor the content and information that we may send or display to you, offer location customization, personalized help and instructions, and otherwise personalize your experience while using the Service. For example, if you allow us to collect geolocation data, we use this information to deliver content related to your specific location and identify business locations/listings around your location. Marketing and promotional purposes. We may use your information to send you news and newsletters, event updates, and to communicate with you about new features, offers, events, or products, or to otherwise contact you about information we think may be of interest to you. Research and reporting. We may use your information to administer surveys and questionnaires (online and offline) for research and reporting purposes to help us better serve individuals by learning more about their needs and the quality of the products, services, and educational information we provide. The survey responses may be utilized to determine the effectiveness of our Service, various types of communications, advertising campaigns and/or promotional activities. Combining information. We (and our third-party business partners on our behalf) may merge, co-mingle, or otherwise combine information, including your personal information, in furtherance of the purposes described above. To comply with legal obligations. We may use your information to comply with our legal obligations or to exercise or defend our rights or the rights of a third party, including complying with law enforcement or government authority requests and participating in compliance audits. To protect us and others. We may use your information where we believe it necessary to investigate, prevent, or take action regarding suspected or actual illegal activities, fraud, situations involving potential threats to the safety of any person, or to otherwise enforce this Policy, our Terms and Conditions, and the integrity of the Service. Deidentified data. We may also deidentify or anonymize your data in such a way that you may not reasonably be re-identified by us or another party, and we may use this deidentified data for any purpose permitted under applicable law. To the extent we deidentify any data originally based on personal information, we will maintain and use such data in deidentified form and will not attempt to reidentify the data. If we want to use your information for any other purpose, we will ask for your consent and use your information only when we receive your consent and then only for the purpose(s) for which consent will be granted, unless we are required by law to do otherwise. We will retain your personal information with us for an unspecified amount of time after user accounts remain idle or for as long as necessary to fulfill the purposes for which it was collected, as detailed in this Privacy Policy. Data Retention Your personal information will be held for only so long as it is necessary for the purpose for which it was originally collected, and in accordance with applicable local law. We will retain your personal information for the period necessary to fulfill the purposes outlined in this Policy. When assessing retention periods, we first examine whether it is necessary to retain the personal information collected and, if retention is required, work to retain the personal information for the shortest possible period permissible under applicable law. To determine the appropriate retention period for personal information, we consider the amount, nature and sensitivity of the personal information, the potential risk of harm from unauthorized use or disclosure of the personal information, the purposes for which we process the personal information, and whether we can achieve those purposes through other means, and the applicable legal, regulatory, tax, accounting or other requirements. How We Disclose the Information We Collect We may disclose each of the categories of personal information described above for our business and commercial purposes as follows: Related Entities. We may disclose the personal information we collect about you to our parent, affiliate, and related entities. Service Providers. We may disclose the personal information we collect about you to service providers, contractors, and agents who perform functions and business operations on our behalf, for the purposes set out above. Third Parties. We may disclose the personal information we collect about you to third-party business partners, such as entities that provide us with advertising and analytics services, as well as business partners with whom we may jointly offer products, services, or educational information or whose products or services we believe may be of interest to you. We may also disclose your personal information in the following circumstances: Business Transfers. If (i) we or our affiliates are or may be acquired by, merged with, or invested in by another company, or (ii) if any of our assets are or may be transferred to another company, whether as part of a bankruptcy or insolvency proceeding or otherwise, we may transfer the information we have collected about you to the other company. As part of the business transfer process, we may disclose certain of your information to lenders, auditors, and third-party advisors, including attorneys and consultants. In Response to Legal Process. We may disclose your personal information to comply with the law, a judicial proceeding, a court order, or other legal process, such as in response to a court order or a subpoena. To Protect Us and Others. We may disclose your personal information where we believe it is appropriate to do so to investigate, prevent, or take action regarding illegal activities, suspected fraud, situations involving potential threats to the safety of any person, violations of our Terms and Conditions, or this Policy, or as evidence in litigation in which we are involved. Aggregate and Deidentified Information. We may disclose aggregate, anonymized, or deidentified information about you for any purpose permitted under applicable law. Consent. We may disclose your personal information with your consent. Our Use of Cookies and Related Technologies When you visit the Site, the Company and third parties may store certain information on your browser, app, or device in the form of a "cookie" or similar file. The Site uses cookies and other technologies to (i) track advertising, (ii) collect traffic data from the Site, and (iii) improve the user experience when using the Site. The user should be aware that, in order to browse the Site, it is not necessary for him or her to allow the installation of cookies sent by the Site. This may only be required in relation to certain services. Most browsers allow you to manage how cookies are set and used as you’re browsing, and to clear cookies and browsing data. Also, your browser may have settings letting you manage cookies on a site-by-site basis. Most mobile devices and applications allow you to manage how similar technologies, such as unique identifiers used to identify an app or device, are set and used. For example, the Advertising ID on Android devices or Apple’s Advertising Identifier can be managed in your device’s settings, while app-specific identifiers may typically be managed in the app’s settings. Cookies. Cookies are small text files containing a string of alphanumeric characters. We may use both session and persistent cookies. A session cookie disappears after you close your browser. A persistent cookie remains after you close your browser and may be used by your browser on subsequent visits to our Site. Please review your browser’s “Help” file to learn the proper way to modify your cookie settings. Please note that if you delete or choose not to accept cookies from the Service, you may not be able to utilize the features of the Service to their fullest potential. To learn more about cookies, visit http://www.allaboutcookies.org . Clear GIFs, pixel tags, and other technologies. Clear GIFs are tiny graphics with a unique identifier, similar in function to cookies. In contrast to cookies, which are stored on your computer’s hard drive, clear GIFs are embedded invisibly on web and app pages. We may use clear GIFs (a.k.a. web beacons, web bugs, or pixel tags) to among other things, track the activities of site visitors, help us manage content, and compile statistics about Service usage. A clear GIF can collect information such as: the IP address of the computer that downloaded the page on which the tag appears; the URL of the page on which the pixel tag appears; the time the page containing the pixel tag was viewed; the browser type and language; the device type; geographic location; and, the identification number of any cookie on the computer previously placed by that server. We and our third-party business partners may also use clear GIFs in HTML emails to our customers to help us track email response rates, identify when our emails are viewed, and track whether our emails are forwarded. Analytics. We may use Google Analytics and other analytics tools to collect information regarding visitor behavior and visitor demographics on our Site. For more information about Google Analytics, please visit www.google.com/policies/privacy/partners . You can opt out of Google’s collection and processing of data generated by your use of the Services by going to http://tools.google.com/dlpage/gaoptout . Interest-based advertising. We may set tracking tools (e.g., cookies, clear GIFs) provided by third-party advertising partners on our site to collect information regarding your activities on our site (e.g., your IP address, page(s) visited, time of day) for advertising purposes. We may also share such information with third-party advertising partners. These advertising partners may use this information (and similar information collected from other websites) for purposes of delivering targeted advertisements to you when you visit non-Site related websites. This practice is commonly referred to as “interest-based advertising” or “online behavioral advertising.” If you do not want interest-based advertising, you may be able to opt-out by visiting US-based https://thenai.org/opt-out/ and www.aboutads.info/choices/ . Data Security We implement physical, technical, and organizational security measures designed to safeguard personal information. These measures are aimed to protect the personal information we collect from loss, misuse, and unauthorized access, disclosure, alteration, and destruction. Please be aware that despite our efforts, no data security measures can guarantee security. Third-Party Links Our Site may contain links to third-party websites. Any access to and use of such linked websites is not governed by this Policy but is instead governed by the privacy policies of those third-party websites. We are not responsible for the information practices of such third-party websites, and we encourage you to review the privacy policies of any third-party sites you choose to visit. Children's Privacy At the Company, we recognize the importance of protecting the privacy of children. Our Service is not intended for children or minors under the age of sixteen years. Accordingly, we do not store information from minors under the age of sixteen years. If you believe that a child has submitted personal information to us, please contact us at our Email Address and we will take reasonable steps to delete the information. We do not knowingly “sell” or “share” the personal information of children under the age of 16. Additional Disclosures Under Applicable Laws You may have certain rights regarding our processing of your personal information under applicable local law. If our processing of your personal information is governed by such laws, this section provides you with additional information regarding your rights and our processing of your personal information under applicable local law. We may disclose each of the categories of personal information described above for our business and commercial purposes. We may “sell” or “share” each of the categories of personal information described above for cross-context behavioral advertising (as those terms are defined under applicable local law). We do not disclose your sensitive personal information for purposes other than permitted under applicable local law. MARKETING COMMUNICATIONS We may send periodic promotional emails to you. You may opt-out of promotional emails by following the opt-out instructions contained in the email. Please note that it may take up to 10 business days for us to process opt-out requests. If you opt-out of receiving promotional emails, we may still send you emails about your account or any services you have requested or received from us. YOUR PRIVACY CHOICES AND RIGHTS Depending on the jurisdiction in which you live, you may have the following rights under applicable local law: Right to request access and a copy of your personal information and information relating to how it is processed; Right to request deletion of your personal information; Right to request the correction or update of the personal information we hold about you; Right to opt-out of “sales” of your personal information and “sharing” of your personal information for cross-context behavioral advertising purposes (as these terms are defined under applicable law) Right to opt-out of targeted advertising; Right to limit our use of your sensitive personal information; Right to not be unlawfully discriminated against for exercising your rights. These rights may be limited or denied in some circumstances. For example, we may retain your personal information where required or permitted under applicable law. You may also opt-out of our “sale” or “sharing” of your personal information through privacy preference signals recognized under applicable local law, such as the Global Privacy Control (GPC), but please note that this signal will be linked to your browser only. For more information on the GPC and how to use a browser or browser extension incorporating the GPC signal, see https://globalprivacycontrol.org/ . VERIFICATION PROCESS In order to protect your information, we will confirm a requestor’s identity before responding to any request. To start the process, you must provide your name and email. We will ask you at least one question, and you must reply by email with the correct answer for each question based on your previous interaction with us. If we still cannot verify your identity as required by applicable laws, we will let you know and may ask additional questions. Otherwise, we will acknowledge your request and contact you later with our full response. We will only send verification questions from our Email Address. Before sending a verification response, please double-check the email address. If you receive an email that appears to be from us but is not from our verification email address listed above, do not respond. Any information we gather through this process will only be used for consumer verification, security procedures, or fraud prevention. We will delete any verification information as soon as practical after processing your request. AUTHORIZED AGENTS You may designate an authorized agent to exercise your rights under applicable laws on your behalf. Pursuant to applicable laws: You must provide the authorized agent written permission to exercise your rights under applicable laws on your behalf. We may deny a request from an authorized agent on your behalf if the authorized agent does not submit proof that he, she, or it has been authorized by you to act on your behalf if we request such proof, as permitted by applicable laws. Even if you use an authorized agent to exercise your rights under applicable laws on your behalf, pursuant to applicable laws we may still require that you verify your own identity directly to us. FINANCIAL INCENTIVES We do not offer financial incentives to collect personal information, and we will not discriminate against you if you exercise any of the rights provided by applicable laws set forth in this Privacy Policy. Please note that a legitimate denial of a request for information, deletion, or to opt-out is not discriminatory, nor is charging a fee for excessive or repetitive consumer requests as permitted by applicable laws. APPEALS You may have a right to appeal a decision we make relating to requests to exercise your rights under applicable local law. To appeal a decision, please contact us at our Email Address. ADDITIONAL CALIFORNIA PRIVACY RIGHTS California Civil Code Section § 1798.83 permits users of our website that are California residents to request certain information regarding our disclosure of personal information to other parties for their direct marketing purposes. To make such a request, please send an email to our Email Address with the subject “Shine the Light Request.” Data Subject Access Requests You have certain data protection rights in certain circumstances. Please contact us if you would like to exercise any of these rights. Withdraw their consent at any time. Users have the right to withdraw consent where they have previously given their consent to the processing of their Personal Data. Object to processing of their Data. Users have the right to object to the processing of their Data if the processing is carried out on a legal basis other than consent. Access their Data. Users have the right to learn if Data is being processed by the Owner, obtain disclosure regarding certain aspects of the processing and obtain a copy of the Data undergoing processing. Verify and seek rectification. Users have the right to verify the accuracy of their Data and ask for it to be updated or corrected. Restrict the processing of their Data. Users have the right to restrict the processing of their Data. In this case, the Owner will not process their Data for any purpose other than storing it. Have their Personal Data deleted or otherwise removed. Users have the right to obtain the erasure of their Data from the Owner. Receive their Data and have it transferred to another controller. Users have the right to receive their Data in a structured, commonly used and machine readable format and, if technically feasible, to have it transmitted to another controller without any hindrance. Lodge a complaint. Users have the right to bring a claim before their competent data protection authority. The deletion of some data shall not be carried out where it may cause damage to the legitimate rights or interests of third parties, or where there is a legal obligation to retain the data. The data owner user may at any time exercise the rights of access, rectification, cancellation, opposition, limitation of processing, portability, confidentiality and deletion of his/her personal data. The exercise of these rights may be carried out by the user him/herself by means of an email addressed to our Email Address, or by any of the methods provided for in the applicable regulations referred to above. The Company may request the data necessary to validate the identification of the data owner. Changes to This Policy? This Policy is current as of the Last Updated date set forth above. We may change this Policy from time to time, so please be sure to check back periodically. If we make any changes to this Policy that materially affect our practices with regard to the information we have previously collected about you, we will endeavor to provide you with notice in advance of such change by highlighting the change on the Site. Contact Us If you have any questions, comments, concerns, or complaints regarding your personal information or our privacy practices, please contact us at our Email Address.